Miambutol

Ethambutol Hydrochloride, the active ingredient in Miambutol, is an antitubercular presented as an oral tablet for systemic use. It is employed in the treatment of tuberculosis, typically as part of multidrug regimens, and is indicated for use in adults and children.

GNH USA supplies Miambutol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides batch‑tested product with full documentation for regulatory compliance. Customers benefit from reliable logistics and responsive technical support.

Ethambutol is a first‑line antitubercular agent used in combination therapy to inhibit mycobacterial cell wall synthesis.

- Pulmonary tuberculosis: contributes to bacterial clearance when combined with other antitubercular agents. - Extrapulmonary tuberculosis: aids in treatment of disseminated disease as part of standard regimens. - Pediatric tuberculosis: used in children under appropriate dosing to achieve effective therapy.

Ethambutol may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Visual disturbances: blurred vision, color‑vision changes. - Gastrointestinal upset: nausea, vomiting, abdominal pain. - Skin reactions: rash, pruritus. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Optic neuritis leading to permanent visual loss. - Severe hypersensitivity reactions including anaphylaxis. - Hepatic dysfunction: elevated transaminases or hepatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute interstitial nephritis.

Before initiating therapy, clinicians should consider several safety measures.

- Visual monitoring: baseline and periodic eye examinations are recommended. - Renal function: assess creatinine clearance and adjust dose in impairment. - Hepatic status: evaluate liver enzymes, especially when combined with other hepatotoxic drugs. - Hypersensitivity: avoid use in patients with known allergy to ethambutol or related compounds. - Elderly patients: start at lower dose and monitor for toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ethambutol can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Isoniazid: increased risk of optic neuritis. - Rifampicin: may reduce ethambutol plasma concentrations. - Streptomycin: heightened neurotoxic potential.

Moderate Interactions (Monitor Closely): - Pyrazinamide: combined hepatotoxic risk. - Antacids containing aluminum or magnesium: may impair absorption. - HIV protease inhibitors: possible pharmacokinetic alterations requiring monitoring.